BSECompany Update1d ago · 17 Nov 2026, 11:18 pm
Please find enclosed intimation
Cipla Ltd · 500087
✦ AI SummaryRegulatory
Cipla Ltd has received a 'No Action Indicated' classification from the USFDA for an inspection at its InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA. The inspection was conducted from October 19 to 22, 2026, and the USFDA's communication dated November 17, 2026, classified the inspection as NAI.
Analysis Scores
Earnings Impact5/10
Growth Catalyst3/10
Governance Concern2/10
Regulatory Risk8/10
Balance Sheet Risk4/10
Liquidity Impact6/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Cipla Ltd - 500087 - Update On USFDA Inspection At Invagen Manufacturing Facility In Hauppauge, Long Island, New York, USA
Attachments (1)
📄pdf
Download →
df40f4ad-c335-43ae-9d24-699bf1273a86.pdf
View document text
17 November, 2026
(1) BSE Limited (2) National Stock Exchange of India Limited
Listing Department, Listing Department
Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor,
Dalal Street, Plot no. C/1, G Block,
Mumbai 400 001 Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: 500087 Scrip Code: CIPLA
(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg
Dear Sir/Madam,
Sub: Update on USFDA inspection at InvaGen manufacturing facility in Hauppauge, Long Island, New
York, USA
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015, and further to our intimation dated 23 October 2026 regarding the inspection conducted by the
United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen
Pharmaceuticals Inc. (InvaGen), a wholly owned subsidiary of the Company, located in Hauppauge,
Long Island, New York, USA, from 19 October 2026 to 22 October 2026, we hereby notify that the
USFDA, vide its communication dated 17 November 2026, has classified the aforementioned
inspection as No Action Indicated (NAI).
Please take the above information on record.
Yours faithfully,
For Cipla Limited
Rajendra Chopra
Company Secretary
Prepared by: Chirag Hotchandani
Cipla Ltd.
Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India
P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380